LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Ground-Breaking Test Assesses Expansion and Persistence of CAR-T Therapy in Cancer Patients

By LabMedica International staff writers
Posted on 21 Feb 2023
Image: ExPeCT CAR-T multiplexed qPCR) assay directly monitors effectiveness of CAR T-cell therapy (Photo courtesy of Eurofins Viracor)
Image: ExPeCT CAR-T multiplexed qPCR) assay directly monitors effectiveness of CAR T-cell therapy (Photo courtesy of Eurofins Viracor)

Chimeric Antigen Receptor T-Cell (CAR-T) therapy is a revolutionary form of immunotherapy that utilizes genetically engineered T-cells to attack cancer cells and has demonstrated promise in treating various types of cancers. Research has shown that the persistence and expansion of CAR-T therapy are important indicators of how long the therapy can remain effective in the patient. Now, a ground-breaking test provides clinicians with an accurate and comprehensive assessment of the CAR-T cell population in the patient's body and offers insights to therapy effectiveness.

Eurofins Viracor LLC (Lenexa, KS, USA) has launched the ExPeCT CAR-T multiplexed quantitative real-time PCR (qPCR) assay that acts as a powerful diagnostic tool to monitor and optimize CAR-T therapy involving patients with pre-B cell acute lymphoblastic leukemia and B cell lymphomas. The test, based on a method developed by Eurofins Viracor, is designed to help clinicians better understand how CAR-T therapy is performing for their patients. The test marks an important step forward in the evaluation and management of CAR-T therapy in cancer patients by helping clinicians to make more informed decisions about the best course of treatment for their patients.

Related Links:
Eurofins Viracor LLC

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Silver Member
PCR Plates
Diamond Shell PCR Plates

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more